ArticlePloS one2018

A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors.

Yasuki Hijikata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.